Compare 10X Genomics Inc (TXG) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Yum China Holdings Inc — how do they compare? 10X Genomics Inc trades at $57.2 (market cap $7.61B), while Yum China Holdings Inc trades at $47.87 (market cap $16.28B). The key difference: Yum China Holdings Inc is far larger — about 2.1× 10X Genomics Inc's market cap, and Yum China Holdings Inc pays a 2.44% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TXG | YUMC | |
|---|---|---|
Market Cap | $7.61B | $16.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $58.57 | $57.95 |
52-Week Low | $11.34 | $40.18 |
Enterprise Value | $7.14B | $17.19B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.
Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.
YUMC trades at $47.77, down 0.87% today, with a bullish technical signal from moving averages and strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating estimates, and revenue growth of 13% year-over-year. Recent completion of the Pizza Hut brand acquisition in Mainland China for $1.2 billion enhances strategic control and potential margin expansion.
Outlook remains positive with consistent earnings beats and analyst consensus favoring a buy rating. Key risks include macroeconomic headwinds in China and integration challenges from the acquisition. The stock offers growth potential with a reasonable P/E of 17.43 and a projected 26.2% upside based on Wall Street targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
